公开(公告)号：US12071425B2

公开(公告)日：2024-08-27

申请号：US17275606

申请日：2019-09-12

Applicant: Genentech, Inc.

Inventor： Marie-Gabrielle Braun ,  Cuong Q. Ly ,  Georgette Castanedo ,  Paul Gibbons ,  Wendy Lee ,  Joachim Rudolph ,  Nicole Alice Blaquiere ,  Jacob Bradley Schwarz ,  Ramsay Beveridge ,  Jean-Philippe Leclerc ,  Alexandre Lemire ,  Leo Fu

IPC: C07D401/14 ,  A61K45/06 ,  C07D401/04 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08

CPC classification number: C07D401/14 ,  A61K45/06 ,  C07D401/04 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08

Abstract: Described herein are phenoxy-pyridyl-pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

公开(公告)号：US20230057166A1

公开(公告)日：2023-02-23

申请号：US17275606

申请日：2019-09-12

Applicant: Genentech, Inc.

Inventor： Marie-Gabrielle Braun ,  Cuong Q. Ly ,  Georgette Castanedo ,  Paul Gibbons ,  Wendy Lee ,  Joachim Rudolph ,  Nicole Alice Blaquiere ,  Jacob Bradley Schwarz ,  Ramsay Beveridge ,  Jean-Philippe Leclerc ,  Alexandre Lemire ,  Leo Fu

IPC: C07D401/14 ,  C07D401/04 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08 ,  A61K45/06

Abstract: Described herein are phenoxy-pyridyl-pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

公开(公告)号：US10968203B2

公开(公告)日：2021-04-06

申请号：US15989008

申请日：2018-05-24

Applicant: Genentech, Inc. ,  The Regents of the University of California

Inventor： Marie-Gabrielle Braun ,  Paul Gibbons ,  Wendy Lee ,  Cuong Ly ,  Joachim Rudolph ,  Jacob Schwarz ,  Avi Ashkenazi ,  Leo Fu ,  Tommy Lai ,  Fei Wang ,  Ramsay Beveridge ,  Liang Zhao

IPC: A61K31/506 ,  A61K45/06 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  A61P35/00

Abstract: Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I′ structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I′ compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

公开(公告)号：US20180265497A1

公开(公告)日：2018-09-20

申请号：US15989008

申请日：2018-05-24

Applicant: Genentech, Inc. ,  The Regents of the University of California

Inventor： Marie-Gabrielle Braun ,  Paul Gibbons ,  Wendy Lee ,  Cuong Ly ,  Joachim Rudolph ,  Jacob Schwarz ,  Avi Ashkenazi ,  Leo Fu ,  Tommy Lai ,  Fei Wang ,  Ramsay Beveridge ,  Liang Zhao

IPC: C07D401/14 ,  A61K31/506 ,  C07D401/04 ,  C07D405/14 ,  C07D417/14 ,  C07D413/14 ,  A61K45/06

CPC classification number: C07D401/14 ,  A61K31/506 ,  A61K45/06 ,  A61P35/00 ,  C07D401/04 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I′ structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I′ compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.